Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology Convergence 2026
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Brixton Metals Announces Closing of Option Agreement to Acquire a 100% Interest in the Silver Focused Silvergruvan Project in Sweden
Spartan Metals Expands Victorio Tungsten-Molybdenum Resource with Measured and Indicated Grades of 0.25% MoEq or 0.15% WO3Eq
